Royal Bank Of Canada Has Lowered Expectations for aTyr Pharma (NASDAQ:ATYR) Stock Price

by · The Markets Daily

aTyr Pharma (NASDAQ:ATYR – Get Free Report) had its target price cut by investment analysts at Royal Bank Of Canada from $40.00 to $6.00 in a research note issued to investors on Friday, Benzinga reports. The firm presently has a “sector perform” rating on the stock. Royal Bank Of Canada‘s price target indicates a potential downside of 6.02% from the company’s current price.

ATYR has been the subject of several other research reports. Wells Fargo & Company raised their price target on shares of aTyr Pharma from $1.00 to $4.00 and gave the company an “equal weight” rating in a research report on Friday. Weiss Ratings cut aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 16th. Finally, Wall Street Zen upgraded aTyr Pharma to a “hold” rating in a research note on Saturday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $5.00.

Check Out Our Latest Stock Analysis on aTyr Pharma

aTyr Pharma Trading Up 5.9%

NASDAQ:ATYR traded up $0.35 on Friday, reaching $6.38. 38,442 shares of the stock traded hands, compared to its average volume of 65,982. The company has a market capitalization of $15.65 million, a price-to-earnings ratio of -0.26 and a beta of 1.04. aTyr Pharma has a 12 month low of $4.07 and a 12 month high of $44.40. The company’s fifty day simple moving average is $11.99 and its 200 day simple moving average is $23.70.

aTyr Pharma (NASDAQ:ATYR – Get Free Report) last issued its earnings results on Friday, November 6th. The company reported ($7.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.00) by ($3.43). Equities analysts anticipate that aTyr Pharma will post -17.80 EPS for the current fiscal year.

Institutional Trading of aTyr Pharma

An institutional investor recently raised its position in aTyr Pharma stock. Bank of America Corp DE grew its stake in shares of aTyr Pharma, Inc. (NASDAQ:ATYR – Free Report) by 139.6% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 303,559 shares of the company’s stock after acquiring an additional 176,859 shares during the quarter. Bank of America Corp DE owned about 0.31% of aTyr Pharma worth $237,000 as of its most recent SEC filing. 61.72% of the stock is currently owned by institutional investors and hedge funds.

aTyr Pharma Company Profile

(Get Free Report)

aTyr Pharma, Inc (NASDAQ:ATYR) is a biotechnology company focused on developing therapies that modulate immune system activity. The company’s research is based on a class of naturally occurring proteins known as extracellular tRNA synthetases, which can influence biological processes involved in inflammation, tissue repair and immune regulation.

aTyr’s lead product candidate is efzofitimod, an engineered protein therapeutic designed to target neuropilin-2 and regulate immune responses in the lungs.

Further Reading